Clinical Trial Update: A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

View source ↗

Summary

A completed study using German health-insurance data compares the costs of treating type 2 diabetes with empagliflozin versus DPP-4 inhibitors and GLP-1 recepto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Dulaglutide (dulaglutide)
• EXENATIDE (EXENATIDE)
• Empagliflozin (empagliflozin)
• Linagliptin (linagliptin)
• Sitagliptin (sitagliptin)
• liraglutide (liraglutide)
• semaglutide (semaglutide)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED | Results posted: 2024-08-30